Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-co-leads-global-lung-cancer-study-supporting-lorlatinib-as-first-line-treatment-option-for-alk-positive-advanced-nsclc-patients
https://www.med.cuhk.edu.hk/press-releases/cuhk-co-leads-global-lung-cancer-study-supporting-lorlatinib-as-first-line-treatment-option-for-alk-positive-advanced-nsclc-patients

CUHK co-leads global lung cancer study Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

Professor Tony Mok Shu-kam from The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) and several other international lung cancer experts joined forces to co-lead a Phase III trial for patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). The trial proved that the third-generation ALK-inhibitor lorlatinib has great potential as the first-line treatment in these patients, with or without brain metastases. Data showed the medicine improved progression-free survival and reduced central nervous system progression versus crizotinib, the first-generation targeted therapy. More importantly, half of all central nervous system adverse events were resolved without intervention or with lorlatinib dose modification. Findings of the study were published in the leading international medical journal Journal of Clinical Oncology.

 

Brain metastases develop in more than half of ALK-positive NSCLC patients

 

Lung cancer is the second most common cancer worldwide, accounting for 1.8 million deaths every year. It is also the leading cause of cancer deaths in Hong Kong, with more than 4,000 new cases every year. Of these, close to 80% suffer from NSCLC and about 5% of these cases are ALK-positive. It is common for lung cancer to spread to the brain, with the risk highest for NSCLC with epidermal growth factor receptor (EGFR) mutation or ALK rearrangement; more than half of these patients will develop brain metastases over the course of their disease.

 

Prof. Tony Mok
Though second-generation ALK-inhibitors alectinib, brigatinib and ensartinib have demonstrated better efficacy in managing patients with brain metastases than crizotinib, the first-generation inhibitor, prognosis among patients with NSCLC and brain metastases remains poor. We are therefore exploring the performance of third-generation inhibitor in managing the disease, especially central nervous system progression,

said Professor Tony Mok, Li Shu Fan Professor of Clinical Oncology and Chairman of CU Medicine’s Department of Clinical Oncology.

Lorlatinib significantly improved progression-free survival and reduced central nervous system progression versus crizotinib
 

The research was a randomised, multicentre, open-label, active-controlled trial conducted in 296 patients with ALK-positive locally advanced or metastatic NSCLC who had not received prior systemic therapy for metastatic disease. Patients were randomly and evenly assigned to either oral lorlatinib 100mg once daily or oral crizotinib 250mg twice daily. They received tumour assessments, including magnetic resonance imaging, at eight-week intervals, and regular assessments of patient-reported outcomes.

 

Results showed that lorlatinib outperformed crizotinib in managing both cancer progression and intracranial activity. The rate of 12-month progression-free survival increased with lorlatinib versus crizotinib in patients with or without brain metastases at baseline (please refer to table 1 for full data). Also, lorlatinib significantly reduced central nervous system progression (please refer to table 2 for full data). Half of central nervous system adverse events were resolved without intervention or with lorlatinib dose modification.

 

Table 1: An overview of the 12-month progression-free survival outcomes in patients with or without brain metastases

 

 

Lorlatinib

Crizotinib

Patients with brain metastases

78%

22%

Patients without brain metastases

78%

45%

Table 2: An overview of the 12-month cumulative incidence of central nervous system progression in patients with or without brain metastases

 

 

Lorlatinib

Crizotinib

Patients with brain metastases

7%

72%

Patients without brain metastases

1%

18%

Professor Mok added, “To stop or reduce brain metastasis progression for advanced NSCLC patients has always been a challenge. We are excited to have discovered the potential of third-generation ALK-inhibitor lorlatinib and changed the clinical practice to the benefit of patients. Based on the findings, the US Food and Drug Administration and the European Commission have granted permission for lorlatinib to be the first-line treatment in patients with metastatic ALK-positive NSCLC.”

More Press Releases

CU Medicine collaborates with South Korean institutes to develop  an AI-powered analytic tool for lung cancer immunotherapy

CU Medicine collaborates with South Korean institutes to develop an AI-powered analytic tool for lung cancer immunotherapy

Research
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

Research
Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Symposium
CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

Surgical advancement
CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

Research
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Response
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
Two CUHK Research Projects Receive State Science and Technology Awards

Two CUHK Research Projects Receive State Science and Technology Awards

Awards and honors

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.